Jones Day is a global law firm with more than 2,500 lawyers across five continents. The Firm is distinguished by a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
On October 23, 2015, the CHMP recommended authorizing Imlygic (talimogene laherparepvec) for the treatment of adults with melanoma that cannot be removed by surgery...
European UnionFood, Drugs, Healthcare, Life Sciences
On October 23, 2015, the CHMP recommended authorizing Imlygic (talimogene
laherparepvec) for the treatment of adults with melanoma that
cannot be removed by surgery and that has spread either to the
surrounding area or to other areas of the body (regionally or
distantly metastatic) without affecting the bones, brain, lung, or
other internal organs. Imlygic is a first-in-class advanced therapy
medicinal product derived from a virus, that has been genetically
engineered to infect and kill cancer cells.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.